NASDAQ · JBIO
Jade Biosciences, Inc.
$13.96-$0.28 (-1.97%)
Jade Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.14% below the high.
Loading market information…
NASDAQ · LABP · USD
Stock price, earnings
Quote as of May 23, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Landos Biopharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.04% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Landos Biopharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Landos Biopharma, Inc. is a biopharmaceutical firm operating in the clinical stage, focused on the discovery and development of innovative oral therapies aimed at treating a range of autoimmune disorders. Their leading clinical-stage candidate, omilancor, is an oral, gut-specific therapeutic designed to modulate lanthionine synthetase C-like protein 2 (LANCL2) activity. It is currently being investigated for treating ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis. Another pipeline asset, NX-13, is also an oral therapeutic localized to the gut, targeting the NOD-like receptor X1 (NLRX1) pathway, a mitochondrial receptor involved in regulating inflammatory cytokine production, for UC and CD. Furthermore, LABP-104 is an oral, small-molecule LANCL2 agonist designed to be systemically bioavailable, with potential applications in systemic lupus erythematosus and rheumatoid arthritis (RA). Beyond these clinical programs, Landos maintains a robust preclinical pipeline, featuring several promising compounds: LABP-66, an oral small molecule, acts as a NOD-like pathway agonist and is being explored for multiple sclerosis and Alzheimer's disease. LABP-69 is an oral PLXDC2 agonist targeting diabetic nephropathy and RA. LABP-73, another oral small molecule, modulates the NLRX1 pathway for potential use in asthma and chronic obstructive pulmonary disease. And LABP-111, an oral small molecule LANCL2 pathway agonist, is under investigation for nonalcoholic steatohepatitis and type 1 diabetes. Established in 2017, the company's corporate headquarters are situated in Blacksburg, Virginia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:31 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Aug 11, 2022 |
| -$2.80+24.32% vs estimate |
| $0.00 |
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$13.96-$0.28 (-1.97%)
Jade Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.14% below the high.
$1.20-$0.08 (-5.88%)
Berkeley Lights, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.78% below the high.
$1.27$0.00 (0.0%)
IGM Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.36% below the high.
$1.07-$0.01 (-0.93%)
Surface Oncology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.17% below the high.
$2.38+$0.01 (+0.42%)
Heat Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 4.03% below the high.
$18.20+$16.47 (+952.02%)
Reneo Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.05% below the high.
$1.48+$0.01 (+0.68%)
Achilles Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 1.99% below the high.
$1.48$0.00 (0.0%)
TCR2 Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.86% below the high.
